Chimerix (CMRX) Competitors $8.54 0.00 (0.00%) As of 04/21/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CMRX vs. VKTX, CRNX, ALVO, SRRK, MRUS, ACAD, CPRX, MOR, PTGX, and MTSRShould you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Scholar Rock (SRRK), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), Protagonist Therapeutics (PTGX), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Chimerix vs. Viking Therapeutics Crinetics Pharmaceuticals Alvotech Scholar Rock Merus ACADIA Pharmaceuticals Catalyst Pharmaceuticals MorphoSys Protagonist Therapeutics Metsera Viking Therapeutics (NASDAQ:VKTX) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation. Do analysts prefer VKTX or CMRX? Viking Therapeutics currently has a consensus target price of $87.15, suggesting a potential upside of 226.87%. Chimerix has a consensus target price of $8.53, suggesting a potential downside of 0.08%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Viking Therapeutics is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in VKTX or CMRX? Viking Therapeutics received 239 more outperform votes than Chimerix when rated by MarketBeat users. Likewise, 80.08% of users gave Viking Therapeutics an outperform vote while only 62.76% of users gave Chimerix an outperform vote. CompanyUnderperformOutperformViking TherapeuticsOutperform Votes63580.08% Underperform Votes15819.92%ChimerixOutperform Votes39662.76% Underperform Votes23537.24% Does the media prefer VKTX or CMRX? In the previous week, Viking Therapeutics had 18 more articles in the media than Chimerix. MarketBeat recorded 18 mentions for Viking Therapeutics and 0 mentions for Chimerix. Viking Therapeutics' average media sentiment score of 1.39 beat Chimerix's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Viking Therapeutics Positive Chimerix Neutral Which has more volatility and risk, VKTX or CMRX? Viking Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500. Which has better valuation & earnings, VKTX or CMRX? Chimerix has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.15-23.19Chimerix$212K3,778.71-$82.10M-$0.99-8.63 Is VKTX or CMRX more profitable? Viking Therapeutics' return on equity of -11.93% beat Chimerix's return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -11.93% -11.57% Chimerix N/A -50.78%-44.94% Do institutionals and insiders hold more shares of VKTX or CMRX? 76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by company insiders. Comparatively, 13.1% of Chimerix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryViking Therapeutics beats Chimerix on 12 of the 17 factors compared between the two stocks. Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRX vs. The Competition Export to ExcelMetricChimerixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$801.09M$6.36B$5.25B$8.49BDividend YieldN/A3.02%4.99%4.16%P/E Ratio-9.098.8626.4519.71Price / Sales3,778.71271.84398.96123.52Price / CashN/A65.8538.3134.62Price / Book3.946.356.684.52Net Income-$82.10M$143.68M$3.22B$248.02M7 Day PerformanceN/A3.69%2.74%4.42%1 Month Performance-0.12%7.87%7.84%12.02%1 Year Performance773.66%-6.86%13.50%5.98% Chimerix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRXChimerix2.083 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990VKTXViking Therapeutics4.6434 of 5 stars$28.30+2.7%$87.15+208.0%-63.4%$3.18BN/A-28.3020CRNXCrinetics Pharmaceuticals3.6043 of 5 stars$33.32+8.6%$73.00+119.1%-36.6%$3.12B$1.04M-8.93210Earnings ReportAnalyst RevisionNews CoverageALVOAlvotech1.8034 of 5 stars$10.25+5.9%$18.00+75.6%-21.3%$3.09B$489.68M-5.544Upcoming EarningsHigh Trading VolumeSRRKScholar Rock4.0988 of 5 stars$32.46+5.8%$42.67+31.4%+118.0%$3.08B$33.19M-13.81140Earnings ReportAnalyst ForecastNews CoveragePositive NewsMRUSMerus3.2583 of 5 stars$42.41+3.7%$85.15+100.8%-9.8%$2.94B$36.13M-10.7437Earnings ReportAnalyst RevisionACADACADIA Pharmaceuticals4.2314 of 5 stars$17.52+0.5%$24.70+41.0%+15.5%$2.93B$957.80M22.46510News CoverageCPRXCatalyst Pharmaceuticals4.6236 of 5 stars$23.83+2.0%$32.29+35.5%+41.9%$2.91B$534.65M20.1980Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.4421 of 5 stars$45.27+5.4%$65.44+44.6%+47.8%$2.80B$207.80M17.02120Analyst RevisionPositive NewsMTSRMetseraN/A$26.38+10.5%$47.00+78.2%N/A$2.77BN/A0.0081Earnings Report Related Companies and Tools Related Companies Viking Therapeutics Competitors Crinetics Pharmaceuticals Competitors Alvotech Competitors Scholar Rock Competitors Merus Competitors ACADIA Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors MorphoSys Competitors Protagonist Therapeutics Competitors Metsera Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRX) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMRX Stock Free CMRX Stock Alerts